Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Stem cell therapy is a promising alternative approach to heart diseases. The most prevalent source of multipotent stem cells, usually called somatic or adult stem cells (mesenchymal stromal/stem cells, MSCs) used in clinical trials is bone marrow (BM-MSCs), adipose tissue (AT-MSCs), umbilical cord (UC-MSCs) and placenta. Therapeutic use of MSCs in cardiovascular diseases is based on the benefits in reducing cardiac fibrosis and inflammation that compose the cardiac remodeling responsible for the maintenance of normal function, something which may end up causing progressive and irreversible dysfunction. Many factors lead to cardiac fibrosis and failure, and an effective therapy is lacking to reverse or attenuate this condition. Different approaches have been shown to be promising in surpassing the poor survival of transplanted cells in cardiac tissue to provide cardioprotection and prevent cardiac remodeling. This review includes the description of pre-clinical and clinical investigation of the therapeutic potential of MSCs in improving ventricular dysfunction consequent to diverse cardiac diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Concise review: MSC-derived exosomes for cell-free therapy
Phinney, D. G., & Pittenger, M. F. (2017) · Stem Cells · doi:10.1002/stem.2575 · Cited by 1,834
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819 · cited 2×
“The most prevalent source of MSCs evaluated in clinical trials from different pathological conditions is bone marrow (BM-MSCs), followed by adipose tissue (AT-MSCs), umbilical cord (UC-MSCs) and placenta [4].”
BackgroundMyofibroblast contraction activates latent TGF-β1 from the extracellular matrix
Wipff, P.-J., Rifkin, D. B., Meister, J.-J., & Hinz, B. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704042 · Cited by 1,346 · cited 1×
“TGF-β1 induces myofibroblasts conversion, which, in addition to ECM proteins, also produces hypertrophic and pro-fibrotic factors [29,36,37].”
BackgroundFibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease
Fan, D., Takawale, A., Lee, J., & Kassiri, Z. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-15 · Cited by 814
Melief, S. M., Zwaginga, J. J., Fibbe, W. E., & Roelofs, H. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0184 · Cited by 442 · cited 1×
“It was also described that the immunomodulatory capacity of AT-MSCs may be higher than that of BM-MSCs [10].”
Background
Cited by
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Hydrogel-based cardiac repair and regeneration function in the treatment of myocardial infarction
Xu, Q., Xiao, Z., Yang, Q., Yu, T., Deng, X., Chen, N., Huang, Y., Wang, L., Guo, J., & Wang, J. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.100978 · Cited by 77
“MSCs can repair injured tissues through a variety of processes, including self-renewal and differentiation, prevent the growth of tissue fibrosis, promote the formation of fibrotic scars, and have good anti-fibrotic properties [169,170].”
BackgroundEmerging technologies for cardiac tissue engineering and artificial hearts
Sun, L., Wang, Y., Xu, D., & Zhao, Y. (2023) · Smart Medicine · doi:10.1002/smmd.20220040 · Cited by 44
Metadata
- Authors
- Gubert, F., da Silva, J. S., Vasques, J. F., de Jesus Gonçalves, R. G., Martins, R. S., de Sá, M. P. L., Mendez-Otero, R., & Zapata-Sudo, G.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-07-12
- Volume
- 22
- Issue
- 14
- Pages
- 7447
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3181397713
- Cited by
- 53
- References
- 6
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.